Asset profile
Ruxolitinib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Atopic Dermatitis, Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease, Vitiligo
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 65 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ruxolitinib: this drug | Approved | Small molecule | JAK1/2 | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Pumecitinib | Phase 3 | Small molecule | JAK1/2 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Imetelstat | Approved | Small molecule | Telomerase | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Remestemcel-L (Ryoncil (approved for pediatric SR-aGvHD)) | Approved | Cell therapy | Allogeneic MSC therapy | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Selinexor | Approved | Small molecule | XPO1 (exportin-1) | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | ||
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 |
…and 52 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(113 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (15)
October 2026 (2)
November 2026 (3)
Phase 2B-Cell MalignanciesActive not recruiting
Est. primary completion 2026-11-05 · NCT04509700 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2026-11-11 · NCT04282187 · CT.gov ↗
What to watch
Phase 2Inborn Errors of ImmunityRecruiting
Est. primary completion 2026-11-21 · NCT06199427 · CT.gov ↗
What to watch
December 2026 (10)
Phase 2Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell TransplantationActive not recruiting
Est. primary completion 2026-12 · NCT03286530 · CT.gov ↗
What to watch
Phase 2DermatomyositisRecruiting
Est. primary completion 2026-12 · NCT06857240 · CT.gov ↗
What to watch
Phase 2Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic SyndromeEnrolling by invitation
Est. primary completion 2026-12 · NCT06987058 · CT.gov ↗
What to watch
Phase 1Hidradenitis SuppurativaRecruiting
Est. primary completion 2026-12-09 · NCT07049575 · CT.gov ↗
What to watch
Phase 2Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm …Recruiting
Est. primary completion 2026-12-10 · NCT07238712 · CT.gov ↗
What to watch
Phase 1Myeloproliferative NeoplasmActive not recruiting
Est. primary completion 2026-12-31 · NCT04041050 · CT.gov ↗
What to watch
Phase 2T-cell Lymphoma, Graft Versus Host Disease, Lymphoma, T-Cell, Peripheral T Cell Lymphoma, T-cell Prolymphocytic Leukemia …Recruiting
Est. primary completion 2026-12-31 · NCT07356245 · CT.gov ↗
What to watch
Phase 3MyelofibrosisRecruiting
Est. primary completion 2026-12-31 · NCT06479135 · CT.gov ↗
What to watch
2027 (45)
January 2027 (3)
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-01 · NCT04454658 · CT.gov ↗
What to watch
Phase 2MyelofibrosisRecruiting
Est. primary completion 2027-01-01 · NCT06345495 · CT.gov ↗
What to watch
February 2027 (4)
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-02 · NCT05371964 · CT.gov ↗
What to watch
Phase 2MyelofibrosisActive not recruiting
Est. primary completion 2027-02 · NCT03069326 · CT.gov ↗
What to watch
Phase 2Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host DiseaseNot yet recruiting
Est. primary completion 2027-02-01 · NCT07197112 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2027-02-06 · NCT03954236 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma …Recruiting
Est. primary completion 2027-03-31 · NCT07278856 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryRecruiting
Est. primary completion 2027-04-01 · NCT06225310 · CT.gov ↗
What to watch
Phase 1MyelofibrosisActive not recruiting
Est. primary completion 2027-04-30 · NCT04279847 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2027-04-30 · NCT04176198 · CT.gov ↗
What to watch
May 2027 (2)
June 2027 (9)
Phase 1Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-06 · NCT02494882 · CT.gov ↗
What to watch
Phase 2Chronic Graft-versus-host-diseaseActive not recruiting
Est. primary completion 2027-06-01 · NCT06388564 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-06-01 · NCT06936566 · CT.gov ↗
What to watch
Phase 2GVHD,Acute, Stem Cell Transplant ComplicationsRecruiting
Est. primary completion 2027-06-01 · NCT07340723 · CT.gov ↗
What to watch
Phase 2Leukemia, Myelodysplasia, Chronic Myelomonocytic LeukemiaRecruiting
Est. primary completion 2027-06-01 · NCT07249346 · CT.gov ↗
What to watch
Phase 2Targeted Therapy, IDH1-Mutated Malignancies, MutationsRecruiting
Est. primary completion 2027-06-01 · NCT07032727 · CT.gov ↗
What to watch
Phase 2/3Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-06-01 · NCT07366801 · CT.gov ↗
What to watch
Phase 2/3Hemophagocytic Lymphohistiocytosis (HLH)Not yet recruiting
Est. primary completion 2027-06-01 · NCT06951971 · CT.gov ↗
What to watch
July 2027 (2)
August 2027 (3)
Phase 1T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte LeukemiaRecruiting
Est. primary completion 2027-08 · NCT05010005 · CT.gov ↗
What to watch
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2027-08 · NCT07661979 · CT.gov ↗
What to watch
September 2027 (4)
Phase 1Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host DiseaseRecruiting
Est. primary completion 2027-09-08 · NCT06008808 · CT.gov ↗
What to watch
Phase 4MyelofibrosisActive not recruiting
Est. primary completion 2027-09-16 · NCT02386800 · CT.gov ↗
What to watch
Early phase / not applicableGraft vs Host DiseaseRecruiting
Est. primary completion 2027-09-25 · NCT07184853 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT02955940 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2MyelofibrosisActive not recruiting
Est. primary completion 2027-10-31 · NCT06909136 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma …Recruiting
Est. primary completion 2027-11-01 · NCT05098210 · CT.gov ↗
What to watch
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2027-11-01 · NCT06756061 · CT.gov ↗
What to watch
December 2027 (9)
Phase 1/2Non Small Cell Lung Carcinoma, Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07219576 · CT.gov ↗
What to watch
Phase 2Polycythemia VeraActive not recruiting
Est. primary completion 2027-12 · NCT02577926 · CT.gov ↗
What to watch
Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia AreataRecruiting
Est. primary completion 2027-12-01 · NCT05398809 · CT.gov ↗
What to watch
Phase 1Graft-versus-Host DiseaseActive not recruiting
Est. primary completion 2027-12-30 · NCT07576010 · CT.gov ↗
What to watch
Phase 2GVHD, Acute, Stem Cell Transplant ComplicationsRecruiting
Est. primary completion 2027-12-30 · NCT07509749 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07548983 · CT.gov ↗
What to watch
Phase 1Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia …Recruiting
Est. primary completion 2027-12-31 · NCT03874052 · CT.gov ↗
What to watch
Phase 3Transplant-Related DisorderNot yet recruiting
Est. primary completion 2027-12-31 · NCT07588945 · CT.gov ↗
What to watch
Phase 4cGVHDNot yet recruiting
Est. primary completion 2027-12-31 · NCT06364319 · CT.gov ↗
What to watch
2028 (28)
January 2028 (4)
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2028-01 · NCT06773195 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma …Recruiting
Est. primary completion 2028-01 · NCT07283822 · CT.gov ↗
What to watch
Phase 4Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Recruiting
Est. primary completion 2028-01-01 · NCT07101588 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (1)
Phase 2Polycythemia VeraRecruiting
Est. primary completion 2028-03-31 · NCT05870475 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia …Active not recruiting
Est. primary completion 2028-05 · NCT05088356 · CT.gov ↗
What to watch
Early phase / not applicableAML, AdultRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
Phase 3MyelofibrosisRecruiting
Est. primary completion 2028-05-17 · NCT07357727 · CT.gov ↗
What to watch
June 2028 (5)
Phase 1/2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8Recruiting
Est. primary completion 2028-06 · NCT06616155 · CT.gov ↗
What to watch
Phase 2Inclusion Body Myositis, SporadicRecruiting
Est. primary completion 2028-06-10 · NCT06536166 · CT.gov ↗
What to watch
Phase 1Hematopoietic and Lymphatic System NeoplasmRecruiting
Est. primary completion 2028-06-22 · NCT07025538 · CT.gov ↗
What to watch
July 2028 (2)
Phase 1Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)Recruiting
Est. primary completion 2028-07-01 · NCT07424222 · CT.gov ↗
What to watch
Phase 2Castleman's Disease (CD), Idiopathic Multicentric Castleman's DiseaseRecruiting
Est. primary completion 2028-07-31 · NCT07085039 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2MyelofibrosisActive not recruiting
Est. primary completion 2028-08-31 · NCT04817007 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-09-30 · NCT02131584 · CT.gov ↗
What to watch
October 2028 (2)
November 2028 (1)
Phase 1/2Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant …Recruiting
Est. primary completion 2028-11-19 · NCT07252050 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2Graft-versus-Host DiseaseRecruiting
Est. primary completion 2028-12 · NCT06660355 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisNot yet recruiting
Est. primary completion 2028-12-01 · NCT07734077 · CT.gov ↗
What to watch
Phase 1B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome …Recruiting
Est. primary completion 2028-12-31 · NCT03017820 · CT.gov ↗
What to watch
Phase 1Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified …Recruiting
Est. primary completion 2028-12-31 · NCT06508463 · CT.gov ↗
What to watch
Phase 2Hemophagocytic LymphohistiocytosesRecruiting
Est. primary completion 2028-12-31 · NCT06160791 · CT.gov ↗
What to watch
Phase 3VitiligoNot yet recruiting
Est. primary completion 2028-12-31 · NCT07595939 · CT.gov ↗
What to watch
2029 (14)
January 2029 (3)
Phase 2Hematologic MalignanciesRecruiting
Est. primary completion 2029-01 · NCT07359859 · CT.gov ↗
What to watch
Phase 1Chronic Graft Versus Host DiseaseRecruiting
Est. primary completion 2029-01-01 · NCT06233110 · CT.gov ↗
What to watch
Phase 1/2T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic LeukemiaRecruiting
Est. primary completion 2029-01-31 · NCT07311746 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells …Active not recruiting
Est. primary completion 2029-02 · NCT03801434 · CT.gov ↗
What to watch
May 2029 (4)
Phase 1Myeloproliferative NeoplasmsRecruiting
Est. primary completion 2029-05 · NCT06291987 · CT.gov ↗
What to watch
Phase 1/2MyelofibrosisRecruiting
Est. primary completion 2029-05-01 · NCT06327100 · CT.gov ↗
What to watch
Phase 4Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host DiseaseRecruiting
Est. primary completion 2029-05-10 · NCT06824103 · CT.gov ↗
What to watch
Phase 1Acute Myeloid Leukemia (AML)Recruiting
Est. primary completion 2029-05-14 · NCT07464951 · CT.gov ↗
What to watch
July 2029 (1)
August 2029 (2)
September 2029 (1)
Phase 2Pyoderma GangrenosumNot yet recruiting
Est. primary completion 2029-09 · NCT07783412 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)Not yet recruiting
Est. primary completion 2029-12 · NCT07566897 · CT.gov ↗
What to watch
Phase 3MyelofibrosisRecruiting
Est. primary completion 2029-12-07 · NCT07623161 · CT.gov ↗
What to watch
2030 (5)
June 2030 (2)
September 2030 (1)
Phase 2MyelofibrosisRecruiting
Est. primary completion 2030-09-01 · NCT07228624 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeRecruiting
Est. primary completion 2030-11-22 · NCT06128070 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult …Recruiting
Est. primary completion 2030-12 · NCT06991101 · CT.gov ↗
What to watch
2031 (2)
2032 (3)
February 2032 (1)
Phase 1/2Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent …Recruiting
Est. primary completion 2032-02-01 · NCT05745714 · CT.gov ↗
What to watch
March 2032 (1)
Phase 1Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host DiseaseRecruiting
Est. primary completion 2032-03-31 · NCT04744116 · CT.gov ↗
What to watch
November 2032 (1)
Phase 2/3Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-diseaseNot yet recruiting
Est. primary completion 2032-11-30 · NCT07297914 · CT.gov ↗
What to watch
2045 (1)
March 2045 (1)
Phase 1Relapsed AML, Refractory AMLActive not recruiting
Est. primary completion 2045-03 · NCT06768476 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.